Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;38(8):615-621.
doi: 10.1089/AID.2021.0195.

Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal

Anthony Twumasi Boateng  1 , Araba Abaidoo-Myles  1 , Evelyn Yayra Bonney  1 , George B Kyei  1   2   3
Affiliations
Review

Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal

Anthony Twumasi Boateng et al. AIDS Res Hum Retroviruses. 2022 Aug.

Abstract

HIV remains incurable due to the persistence of a latent viral reservoir found in HIV-infected cells, primarily resting memory CD4+ T cells. Depletion of this reservoir may be the only way to end this deadly epidemic. In latency, the integrated proviral DNA of HIV is transcriptionally silenced partly due to the activity of histone deacetylases (HDACs). One strategy proposed to overcome this challenge is the use of HDAC inhibitors (HDACis) as latency reversal agents to induce viral expression (shock) under the cover of antiretroviral therapy. It is hoped that this will lead to elimination of the reservoir by immunologic and viral cytopathic (kill). However, there are 18 isoforms of HDACs leading to varying selectivity for HDACis. In this study, we review HDACis with emphasis on their selectivity for HIV latency reversal.

Keywords: HDAC inhibitors; HIV; latency reversal; shock and kill; viral reservoir.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Chromatin organization of HIV LTR (promoter) and its association with HDACs and transcription factors in the setting of HIV latency. The HIV promoter is arranged in two nucleosomes (nuc 0 and nuc 1) consisting of two copies each of the core histones H2A (black), H2B (blue), H3 (orange), and H4 (green). The nucleotide +1 denotes transcriptional start site on the viral promoter. Transcription factors like RBF2, p50, CTIP2, Sp1, YY1, AP-4, and LSF recruit HDACs to the HIV LTR. These HDACs, in part, promote HIV latency by deacetylating the local histones directly at the provirus integrated site, which in turn brings about repression of chromatin and prevention of RNA polymerase II from binding. HDAC inhibitors block these HDACs and induce histone acetylation, which leads to reactivation of the HIV LTR. AP-4, activating enhancer binding protein; CTIP2, COUP-TF interacting protein; HDACs, histone deacetylases; LSF, late SV40 factor; LTR, long terminal repeats; RBF2, retinoblastoma-family protein 2; YY1, Ying Yang 1.
FIG. 2.
FIG. 2.
Basic chemical structures of some representative HDAC inhibitors from different families.
See this image and copyright information in PMC

References

    1. Barré-sinoussi F, Ross AL, Delfraissy J. Past, present and future: 30 years of HIV research. Nat Publ Gr 2013;11:877–883. - PubMed
    1. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012;90:47–54. - PubMed
    1. Trono D, Van LC, Rouzioux C, et al. HIV Persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010;329:174. - PubMed
    1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009;323:1304–1307. - PubMed
    1. Ait-Ammar A, Kula A, Darcis G, et al. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol 2020;10:3060. - PMC - PubMed

Publication types

Substances